Literature DB >> 11329060

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.

T W Synold1, I Dussault, B M Forman.   

Abstract

Cytochrome P450 3A4 is an important mediator of drug catabolism that can be regulated by the steroid and xenobiotic receptor (SXR). We show here that SXR also regulates drug efflux by activating expression of the gene MDR1, which encodes the protein P-glycoprotein (ABCB1). Paclitaxel (Taxol), a commonly used chemotherapeutic agent, activated SXR and enhanced P-glycoprotein-mediated drug clearance. In contrast, docetaxel (Taxotere), a closely related antineoplastic agent, did not activate SXR and displayed superior pharmacokinetic properties. Docetaxel's silent properties reflect its inability to displace transcriptional corepressors from SXR. We also found that ET-743, a potent antineoplastic agent, suppressed MDR1 transcription by acting as an inhibitor of SXR. These findings demonstrate how the molecular activities of SXR can be manipulated to control drug clearance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329060     DOI: 10.1038/87912

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  201 in total

1.  Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes.

Authors:  Jian Yang; Chunshu Hao; Dongfang Yang; Deshi Shi; Xiulong Song; Xiaofei Luan; Gang Hu; Bingfang Yan
Journal:  Toxicol Lett       Date:  2010-06-09       Impact factor: 4.372

2.  Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.

Authors:  Jan-Hendrik Beumer; Tessa Buckle; Mariet Ouwehand; Niels E F Franke; Luis Lopez-Lazaro; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

Review 3.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

Review 4.  Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily.

Authors:  Tomas Smutny; Sridhar Mani; Petr Pavek
Journal:  Curr Drug Metab       Date:  2013-12       Impact factor: 3.731

5.  Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme.

Authors:  Xue-Ding Wang; Jia-Li Li; Qi-Biao Su; Su Guan; Jie Chen; Jun Du; Yu-Wen He; Jun Zeng; Jin-Xin Zhang; Xiao Chen; Min Huang; Shu-Feng Zhou
Journal:  Br J Clin Pharmacol       Date:  2008-12-01       Impact factor: 4.335

6.  Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.

Authors:  Laurence Bousquet; Alain Pruvost; Anne-Cécile Guyot; Robert Farinotti; Aloïse Mabondzo
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Authors:  J H Beumer; N E Franke; R Tolboom; T Buckle; H Rosing; L Lopez-Lazaro; J H M Schellens; J H Beijnen; O van Tellingen
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

Review 8.  Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.

Authors:  Sridhar Mani; Mohammed Ghalib; Imran Chaudhary; Sanjay Goel
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-02       Impact factor: 4.481

9.  Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients.

Authors:  Yuichi Uwai; Satohiro Masuda; Maki Goto; Hideyuki Motohashi; Hideyuki Saito; Masahiro Okuda; Eijirou Nakamura; Noriyuki Ito; Osamu Ogawa; Ken-Ichi Inui
Journal:  J Hum Genet       Date:  2003-12-18       Impact factor: 3.172

10.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.